|
Tipo |
Pubblicazione |
3 |
Rivista |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
12 |
Rivista |
Owens LC, Fleming RA, Restino MS, Cruz JM, Hurd DD. Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. Am J Health-Syst Pharm 1997 ; 54: 683-686. |
36 |
Rivista |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
59 |
Rivista |
Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
73 |
Rivista |
Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159. |
81 |
Rivista |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
Rivista |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
99 |
Rivista |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
169 |
Rivista |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
Rivista |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
198 |
Rivista |
Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
201 |
Rivista |
Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531. |
215 |
Rivista |
Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426. |
244 |
Rivista |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
248 |
Rivista |
Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304. |
249 |
Rivista |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
251 |
Rivista |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
253 |
Rivista |
Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528. |
256 |
Rivista |
Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208. |
265 |
Rivista |
Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health-Syst Pharm 1995 ; 52: 1463-1464. |
266 |
Rivista |
Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
270 |
Rivista |
Heide PE. Precipitation of amphotericin B from IV fat emulsion. Am J Health-Syst Pharm 1997 ; 54: 1449. |
280 |
Rivista |
Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
283 |
Rivista |
Lee MD, Hess MM, Boucher BA, Apple AM. Stability of amphotericin B in 5% dextrose injection stored at 4 or 25°C for 120 hours. Am J Hosp Pharm 1994 ; 51: 394-396. |
285 |
Rivista |
Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255. |
299 |
Rivista |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
300 |
Rivista |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
301 |
Rivista |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
307 |
Rivista |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
334 |
Rivista |
Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992. |
335 |
Rivista |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
337 |
Rivista |
Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533. |
435 |
Rivista |
Wiest DB, Maish WA, Garner SS, El-Chaar GM. Stability of amphotericin B in four concentrations of dextrose injection. Am J Hosp Pharm 1991 ; 48: 2430-2433. |
436 |
Rivista |
Mitrano FP, Outman WR, Baptista RJ, Palombo JD. Chemical and visual stability of amphotericin B in 5% dextrose injection stored at 4°C for 35 days. Am J Hosp Pharm 1991 ; 48: 2635-2637. |
439 |
Rivista |
Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at concentrations used for administration through a central venous line. Am J Hosp Pharm 1991 ; 48: 283-285. |
479 |
Rivista |
Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966. |
492 |
Rivista |
Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
496 |
Rivista |
Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746. |
497 |
Rivista |
Kintzel PE, Kennedy PE. Stability of amphotericin B in 5% dextrose injection at 25°C. Am J Hosp Pharm 1991 ; 48: 1681. |
604 |
Laboratorio |
Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998 |
682 |
Rivista |
Raymond GG, Davis RL. Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection. Ann Pharmacotherapy 1991 ; 25: 123-126. |
793 |
Rivista |
Ranch?re JY, Latour JF, Fuhrmann C, Lagallarde C, Loreuil F. Amphotericin B intralipid formulation: stability and particule size. J Antimicrob Chemother 1996 ; 37: 1165-1169. |
892 |
Rivista |
Kintzel PE, Smith GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm 1992 ; 49: 1156-1164. |
905 |
Rivista |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
984 |
Rivista |
Ericsson O, Hallmen AC, Wikstrom I. Amphotericin B is incompatible with lipid emulsions. Ann Pharmacotherapy 1996 ; 30: 298. |
1057 |
Rivista |
Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
1135 |
Rivista |
Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077. |
1172 |
Rivista |
Jurgens RW, DeLuca PP, Papadimitriou D. Compatibility of amphotericin B with certain large-volume parenterals. Am J Hosp Pharm 1981 ; 38: 377-378. |
1201 |
Rivista |
Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922. |
1410 |
Rivista |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1415 |
Rivista |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
1423 |
Rivista |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1498 |
Rivista |
Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacotherapy 1996 ; 30: 409-412. |
1611 |
Rivista |
Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506. |
1625 |
Rivista |
Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
1703 |
Rivista |
Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103. |
1712 |
Rivista |
Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
1713 |
Rivista |
Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
1721 |
Rivista |
Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
1754 |
Rivista |
Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244. |
1803 |
Rivista |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
1907 |
Rivista |
Burger DE, Caldwell JW. Sustaining treatment of coccidioidal meningitidis by extending the stability of amphotericin B. Hosp Pharm 2004 ; 39: 554-557. |
1925 |
Rivista |
Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
1953 |
Rivista |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
1982 |
Rivista |
Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837. |
2043 |
Rivista |
Walker S, Tailor SAA, Lee M, Louie L, Louie M, Simor AE. Amphotericin B in lipid emulsion : stability, compatibility, and in vitro antifungal activity. Antimicrob Agents Chemother 1998 ; 42: 762-766. |
2090 |
Rivista |
Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
2247 |
Rivista |
Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278. |
2262 |
Rivista |
Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
2269 |
Rivista |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
3152 |
Rivista |
Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
3216 |
Rivista |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18 |
3249 |
Rivista |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
3254 |
Rivista |
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
3332 |
Laboratorio |
Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012 |
3408 |
Rivista |
Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
3539 |
Laboratorio |
Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013 |
3549 |
Laboratorio |
Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012 |
3560 |
Laboratorio |
Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013 |
3564 |
Laboratorio |
Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012 |
3585 |
Laboratorio |
Benzylpenicillin sodium - Summary of Product Characteristics Genus Pharmaceuticals 2008 |
3591 |
Laboratorio |
Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit Bristol Myers Squibb 2011 |
3638 |
Laboratorio |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010 |
3644 |
Laboratorio |
Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
3662 |
Laboratorio |
Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014 |
3766 |
Rivista |
Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165. |
3767 |
Rivista |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. |
3791 |
Poster |
Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014 |
3828 |
Poster |
Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
3829 |
Poster |
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
3869 |
Rivista |
Sun P, Chen J, Zhang Z, Gao X, Chen P, Li X. Influence of 5% dextrose volume on amphotericin B deoxycholate preparation J Pharm Pharmacol 2016 ; 68: 433-438. |
3871 |
Poster |
Soussi M.A, Soualah-alila R, jenene F, Lazreg O, Razgallah Khrouf M. Peut-on administrer le céfotaxime en Y avec d'autres médicaments injectables ? Synprefh Congress Clermont Ferrand, France 2016 |
3883 |
Laboratorio |
Ceftazidime - Résumé des caractéristiques du produit Arrow 2016 |
3968 |
Laboratorio |
Ringer lactate - Résumé des Caractéristiques du Produit Fresenius Kabi 2015 |
4055 |
Rivista |
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
4145 |
Rivista |
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056 |
4528 |
Rivista |
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61 |
4543 |
Rivista |
Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295. |
4650 |
Laboratorio |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |